{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:34:10Z","timestamp":1790771650479,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Canakinumab is an anti-interleukin-1\u03b2 monoclonal antibody approved for use in a range of immune-related disorders. During the clinical investigation (CANTOS trial) for prevention of cardiovascular complications, therapy was linked to a reduction in both the occurrence and mortality of lung cancer. This unexpected observation fuelled the rapid initiation of four large clinical trials to evaluate potential anticancer efficacy (in combination with chemotherapy and\/or immunotherapy), before fully validating these observations in a dedicated study. The first two trials (CANOPY-1 and 2) have now been reported and have both have failed to meet their primary efficacy endpoints. In this article, we explore the scientific and clinical rationale behind the development of canakinumab in oncology, the repurposing approach utilised and implications this may have for the wider drug repurposing field in the development of new cancer medicines.<\/jats:p>","DOI":"10.1038\/s41416-022-01893-5","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T16:36:44Z","timestamp":1656002204000},"page":"785-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Repositioning canakinumab for non-small cell lung cancer\u2014important lessons for drug repurposing in oncology"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-7639","authenticated-orcid":false,"given":"Mark P.","family":"Lythgoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"1893_CR1","unstructured":"Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer | Novartis n.d. https:\/\/www.novartis.com\/news\/media-releases\/novartis-top-line-results-canopy-1-phase-iii-study-support-further-evaluation-canakinumab-lung-cancer (accessed October 29, 2021)."},{"key":"1893_CR2","doi-asserted-by":"publisher","first-page":"S953","DOI":"10.1016\/j.annonc.2021.08.1799","volume":"32","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Goto Y, Lim WDT, Halmos B, Cho BC, Dols MC, et al. 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2\/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann Oncol. 2021;32:S953\u20134.","journal-title":"Ann Oncol"},{"key":"1893_CR3","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, Everett B, Libby P, Glynn R, et al. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833\u201342.","journal-title":"Lancet"},{"key":"1893_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883\u201399.","journal-title":"Cell"},{"key":"1893_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4143\/crt.2013.45.4.325","volume":"45","author":"J-W Kim","year":"2013","unstructured":"Kim J-W, Koh Y, Kim D-W, Ahn Y-O, Kim TM, Han S-W, et al. Clinical implications of VEGF, TGF-\u03b21, and IL-1\u03b2 in patients with advanced non-small cell lung cancer. Cancer Res Treat. 2013;45:325","journal-title":"Cancer Res Treat"},{"key":"1893_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","volume":"39","author":"C Garlanda","year":"2021","unstructured":"Garlanda C, Mantovani A. Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell. 2021;39:1023\u20137.","journal-title":"Cancer Cell"},{"key":"1893_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrclinonc.2017.27","volume":"14","author":"B Gyawali","year":"2017","unstructured":"Gyawali B, Prasad V. Drugs that lack single-agent activity: are they worth pursuing in combination. Nat Rev Clin Oncol. 2017;14:193\u20134.","journal-title":"Nat Rev Clin Oncol"},{"key":"1893_CR8","doi-asserted-by":"publisher","first-page":"e202488","DOI":"10.1001\/jamanetworkopen.2020.2488","volume":"3","author":"S Parsons","year":"2020","unstructured":"Parsons S, Maldonado EB, Prasad V. Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non\u2013small cell lung cancers. JAMA Netw Open. 2020;3:e202488\u2013e202488.","journal-title":"JAMA Netw Open"},{"key":"1893_CR9","unstructured":"Drugs@FDA: FDA-Approved Drugs n.d. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed April 2022)."},{"key":"1893_CR10","doi-asserted-by":"crossref","unstructured":"AACR Annual Meeting 2022 Itinerary Planner | Presentation CT037 - Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): results from the CANOPY-1 phase 3 trial https:\/\/www.abstractsonline.com\/pp8\/#!\/10517\/presentation\/20382 (accessed April 28, 2022).","DOI":"10.1158\/1538-7445.AM2022-CT037"},{"key":"1893_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","volume":"32","author":"M Hay","year":"2014","unstructured":"Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40\u201351.","journal-title":"Nat Biotechnol"},{"key":"1893_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20:273\u201386.","journal-title":"Biostatistics"},{"key":"1893_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl J Med. 1999;341:1565\u201371.","journal-title":"N. Engl J Med"},{"key":"1893_CR14","doi-asserted-by":"publisher","first-page":"e543.","DOI":"10.1016\/S1470-2045(20)30610-0","volume":"21","author":"M Frantzi","year":"2020","unstructured":"Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A. Drug repurposing in oncology. Lancet Oncol. 2020;21:e543.","journal-title":"Lancet Oncol"},{"key":"1893_CR15","doi-asserted-by":"publisher","unstructured":"Begley CG, Ashton M, Baell J, Bettess M, Brown MP, Carter B, et al. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021;13. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABD5524.","DOI":"10.1126\/SCITRANSLMED.ABD5524"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01893-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01893-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T23:09:35Z","timestamp":1661900975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01893-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01893-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VP: research funding from Arnold Ventures; royalties from Johns Hopkins Press and Medscape; honoraria from Grand Rounds\/lectures from universities, medical centres, non-profits and professional societies; consulting fees from UnitedHealthcare; and speaking fees from Evicore. MPL has received advisory fees from Clovis Oncology outside the submitted work. Other: Plenary Session podcast has Patreon backer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}